Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Oct. 21, 2025	Posted Integrated Report 2025	Others
Oct. 14, 2025	Sumitomo Pharma and Novo Nordisk Pharma Enter into a Co-Promotion Agreement for Wegovy Subcutaneous Injection, a Treatment for Obesity Disease, in Japan	Licensing
Oct. 14, 2025	Sumitomo Pharma Presents Latest Clinical Data on Investigational Anti-Cancer Agent Enzomenib (DSP-5336) at the 2025 Annual Meeting of the Japanese Society of Hematology (JSH)	R&D
Oct. 01, 2025	Academic Conference Presentation on the Results of Phase 1 Clinical Study in Europe on a Novel Universal Influenza Vaccine Candidate Formulated with Sumitomo Pharma’s Proprietary TLR7 Adjuvant (DSP-0546)	R&D
Sep. 02, 2025	Sumitomo Pharma Announces Organizational Realignments and Personnel Changes	Corporate
Aug. 29, 2025	Sumitomo Pharma Selected for Five Inclusions as a Constituent of GPIF-Adopted ESG Indexes	Sustainability

Oct. 31, 2025	2nd Quarter of FY2025 financial results announcement, conference on 2nd quarter FY2025 financial results for Analysts, Investors, and the Press (planned, 3:30 p.m.)